Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash & Equivalents (2016 - 2025)

Fate Therapeutics' Cash & Equivalents history spans 14 years, with the latest figure at $46.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 29.32% year-over-year to $46.6 million; the TTM value through Dec 2025 reached $46.6 million, up 29.32%, while the annual FY2025 figure was $46.6 million, 29.32% up from the prior year.
  • Cash & Equivalents reached $46.6 million in Q4 2025 per FATE's latest filing, up from $40.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $133.6 million in Q4 2021 to a low of $33.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $63.9 million, with a median of $46.7 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 82.3% in 2021, then surged 188.72% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $133.6 million in 2021, then crashed by 54.09% to $61.3 million in 2022, then tumbled by 31.73% to $41.9 million in 2023, then dropped by 13.89% to $36.1 million in 2024, then rose by 29.32% to $46.6 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Cash & Equivalents are $46.6 million (Q4 2025), $40.6 million (Q3 2025), and $41.2 million (Q2 2025).